Skip to content
Skip to footer

Akari Therapeutics

A Revolution in Treating Complement & Orphan Diseases

Main navigation

HOME
ABOUT
- Close
- MANAGEMENT
- BOARD OF DIRECTORS
PRODUCT PIPELINE
THE SCIENCE
INVESTOR RELATIONS
- Close
- OVERVIEW
- FINANCIAL INFORMATION
  - Close
  - SEC FILINGS
  - ANNUAL REPORTS
- NEWS & EVENTS
  - Close
  - PRESS RELEASES
  - EVENTS
  - PRESENTATIONS
- STOCK INFORMATION
- CORPORATE GOVERNANCE
- INVESTOR RESOURCES
  - Close
  - INVESTOR FAQS
  - EMAIL ALERTS
PRESS
- Close
- PRESS RELEASES
- PUBLICATIONS
CONTACT US

Main Content

A REVOLUTION IN

TREATING COMPLEMENT

& ORPHAN DISEASES

VIEW PRESENTATION

VIEW FACT SHEET

VIEW PRESENTATION

VIEW FACT SHEET

We are developing anti-complement and anti-inflammatory molecules as life-transforming treatments for a wide range of severe and orphan autoimmune and inflammatory diseases.

PRESS RELEASES

Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress

March 21, 2018

Akari Therapeutics to Present at the Leerink Partners Global Healthcare Conference

February 7, 2018

Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials

February 6, 2018

Footer

LONDON

75/76 Wimpole Street London W1G 9RT UK

T: +44 (0)20.8004.0261
E: info@Akaritx.com

NEW YORK

24 W. 40th Street. 8th Fl New York, NY, 10018

T: 646.350.0702
F: 646.843.9352
E: info@Akaritx.com

Copyright © 2018 · Site Designed by Polus Digital, Inc.